- Home
- ACAD vs SSL Comparison
ACAD vs SSL Comparison
Compare ACAD & SSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- SSL
- Stock Information
- Founded
- ACAD 1993
- SSL 1950
- Country
- ACAD United States
- SSL South Africa
- Employees
- ACAD N/A
- SSL N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- SSL Oil & Gas Production
- Sector
- ACAD Health Care
- SSL Energy
- Exchange
- ACAD Nasdaq
- SSL Nasdaq
- Market Cap
- ACAD 4.3B
- SSL 4.0B
- IPO Year
- ACAD 2004
- SSL N/A
- Fundamental
- Price
- ACAD $24.67
- SSL $6.95
- Analyst Decision
- ACAD Buy
- SSL
- Analyst Count
- ACAD 21
- SSL 0
- Target Price
- ACAD $29.30
- SSL N/A
- AVG Volume (30 Days)
- ACAD 1.8M
- SSL 1.4M
- Earning Date
- ACAD 11-05-2025
- SSL 01-01-0001
- Dividend Yield
- ACAD N/A
- SSL N/A
- EPS Growth
- ACAD 615.00
- SSL N/A
- EPS
- ACAD 1.33
- SSL 0.59
- Revenue
- ACAD $1,018,885,000.00
- SSL $14,028,282,389.00
- Revenue This Year
- ACAD $14.01
- SSL $0.32
- Revenue Next Year
- ACAD $11.72
- SSL $5.91
- P/E Ratio
- ACAD $18.55
- SSL $11.84
- Revenue Growth
- ACAD 14.41
- SSL N/A
- 52 Week Low
- ACAD $13.40
- SSL $2.78
- 52 Week High
- ACAD $26.65
- SSL $7.34
- Technical
- Relative Strength Index (RSI)
- ACAD 49.69
- SSL 61.94
- Support Level
- ACAD $23.34
- SSL $6.88
- Resistance Level
- ACAD $25.90
- SSL $7.15
- Average True Range (ATR)
- ACAD 0.78
- SSL 0.12
- MACD
- ACAD -0.28
- SSL -0.03
- Stochastic Oscillator
- ACAD 40.18
- SSL 61.04
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About SSL Sasol Ltd.
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: Southern Africa Energy & Chemicals business; and International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business. The company operates coal mines and its upstream interests in oil and gas, both of which are used as feedstock in the company's energy and chemicals operations. Geographically the company generates the majority of its revenue from South Africa.